New Hope for Dogs with Metastatic OSA: Insights from the Minimally Invasive Metastasectomy In Canines (MIMIC) Trial

Presentation Description / Summary: While local control of OS in humans and dogs is often manageable, metastasis continues to be the prevailing and deadly common denominator in both species. The human OS development pathway includes a unique phase 2 trial design that examines novel therapeutics at the time of pulmonary recurrence. This investigational approach is currently being evaluated in veterinary oncology through the Ethos Discovery MIMIC study (Minimally Invasive Metastasectomy In Canines) to create a path to study the biology of metastasis in the dog, and build an integrated pathway to prioritize novel therapeutics through interrogation of metastatic tissue samples. Until now, metastasectomy has rarely been performed due to the perceived invasiveness of the procedure. Our preliminary data suggest thoracoscopic metastasectomy is associated with little morbidity and hints at an improved long-term outlook. Ethos Discovery seeks to evolve the existing perspective regarding OS metastasis in dogs and close the integration gap by leveraging our successfully recruiting MIMIC trial to create highly productive partnerships that align the dog model with the OS patients of highest need, those with distant metastasis. In this presentation we will introduce high level collaborations, share our progress and review preliminary findings from the high-level clinical and genomic evidence regarding Ethos-MIMIC clinical trial which suggests that there is more hope for patients with stage III OS.

Learner Outcomes: 1. Understand that there are well tolerated and relatively accessible therapeutic options for dogs with stage III OSA. 2. Understand that high level collaborations with experts in the human field will accelerate our discoveries and help both species. 3. Understand that previously undruggable targets may not be accessible through a variety of new targeting techniques.